The therapeutic molecules generated from Elpiscience’s novel BiME® (bispecific antibody macrophage engager) platform have the potential of changing the clinical practice for tumors where tumor-associated macrophages are highly abundant, and no effective therapies are available.
Base on the BiME® platform, we will continue to develop the multiple candidates, and to maximize the value of the innovative platform.
